Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 AUD | +1.53% |
|
+3.52% | +39.11% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company sustains low margins.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+39.11% | 41Cr | B+ | ||
-17.80% | 838.36Cr | B+ | ||
+69.40% | 429.39Cr | C+ | ||
+6.60% | 273.47Cr | B- | ||
-2.10% | 262.43Cr | - | ||
-55.57% | 185.38Cr | B- | ||
-17.55% | 169.6Cr | C- | ||
-17.29% | 142.72Cr | A- | ||
+15.43% | 119.12Cr | B+ | ||
-49.10% | 106.23Cr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IDX Stock
- Ratings Integral Diagnostics Limited